- Home
- TOVX vs GLTO Comparison
TOVX vs GLTO Comparison
Compare TOVX & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- GLTO
- Stock Information
- Founded
- TOVX 2001
- GLTO 2011
- Country
- TOVX United States
- GLTO Denmark
- Employees
- TOVX N/A
- GLTO N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- TOVX Health Care
- GLTO Health Care
- Exchange
- TOVX Nasdaq
- GLTO Nasdaq
- Market Cap
- TOVX 4.5M
- GLTO 4.5M
- IPO Year
- TOVX 2006
- GLTO 2020
- Fundamental
- Price
- TOVX $0.42
- GLTO $3.34
- Analyst Decision
- TOVX Hold
- GLTO Buy
- Analyst Count
- TOVX 1
- GLTO 1
- Target Price
- TOVX N/A
- GLTO $10.00
- AVG Volume (30 Days)
- TOVX 1.2M
- GLTO 19.6K
- Earning Date
- TOVX 08-11-2025
- GLTO 08-05-2025
- Dividend Yield
- TOVX N/A
- GLTO N/A
- EPS Growth
- TOVX N/A
- GLTO N/A
- EPS
- TOVX N/A
- GLTO N/A
- Revenue
- TOVX N/A
- GLTO N/A
- Revenue This Year
- TOVX N/A
- GLTO N/A
- Revenue Next Year
- TOVX N/A
- GLTO N/A
- P/E Ratio
- TOVX N/A
- GLTO N/A
- Revenue Growth
- TOVX N/A
- GLTO N/A
- 52 Week Low
- TOVX $0.37
- GLTO $2.01
- 52 Week High
- TOVX $7.15
- GLTO $14.88
- Technical
- Relative Strength Index (RSI)
- TOVX 44.90
- GLTO 45.88
- Support Level
- TOVX $0.45
- GLTO $3.26
- Resistance Level
- TOVX $0.47
- GLTO $3.48
- Average True Range (ATR)
- TOVX 0.04
- GLTO 0.15
- MACD
- TOVX 0.00
- GLTO -0.00
- Stochastic Oscillator
- TOVX 31.76
- GLTO 51.52
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.